The association of coronaviruses with humans was relatively obscure, probably because there was no severe human disease that could be attributed to the virus. However, this myth busted with the acquaintance of severe acute respiratory syndrome (SARS)-CoV in 2003, proceeded by Middle East respiratory syndrome (MERS)-CoV in 2012, which served as a great public health threat. To replenish and regain its importance in humans, a new member of the family known as SARS-2 (SARS-CoV-2), which caused coronavirus disease-2019 (COVID-19) initially identified by causing pneumonia-like symptoms in a cluster of patients in Wuhan, China in late December 2019. The World Health Organization (WHO) initially declared it as a public health emergency of international concern (PHEIC) on the last day of January 2020 and later on March 11, 2020 upgraded its status to a pandemic with more than 118,000 cases spread across 114 countries. As of February 21, 2021, it has spread worldwide, causing over 110.7 million cases and over 2.4 million deaths across the world, with India having the second-highest number of COVID-19 cases, following the United States of America. Furthermore, a cross-sectional view of the disease states several new strains being reported across the globe at one end and at another end there is rolling out of vaccine against COVID-19. There is still uncertainty related to curbing of the pandemic as effect of vaccine on new strains is undetermined. Thus, it is important to understand the transforming epidemiology of the virus as it helps in planning necessary steps for physicians and policymakers. The present review summarizes the updated information primarily about the epidemiology of COVID-19, from initiation to the present scenario.

Keywords: COVID-19, epidemiology, lockdown, pandemic, social distancing, vaccine
transmissibility of these strains. On the other hand, around 12 vaccines have been rolled out. At present, there is uncertainty regarding the effectiveness of vaccine on the newer strains, hence it is important to continue following stringent preventive measures.[10] Thus, more attention is required for understanding each and every aspect of the virus, so that important strategy can be planned by physicians and policymakers. Moreover, due to ever-evolving nature of this infection, all updates and changes in its epidemiology should be discussed with all physicians, especially those who are involved in primary care, diagnosis, or the ones involved in the treatment of the COVID-19 cases as they are the backbone of the health care delivery system in the periphery. Therefore, through this review, we aim to summarize the updated information of the ever-changing COVID-19 pandemic from initiation to the current status.

**Description of the Virus**

Coronavirus is an enveloped, single-stranded positive-sense RNA virus that is classified within the Nidovirales order and belonged to lineage β-CoVs, subgenus Sarbecovirus. The envelope of the virus is covered with glycoprotein arranged in a typical crown-like appearance under an electron microscope, hence named coronavirus.[11] It is spherical or pleomorphic in shape ranging from 60 nm to 140 nm in diameter. It has four major proteins: spike (S), envelope (E), membrane (M), and nucleo-capsid (N).[12] Though coronavirus is found in several animals, the major natural reservoirs are bats.[13,14]

**Origin and Spread of COVID-19 across the World**

The first case with unknown etiology was reported in December 2019 in Central Hospital of Wuhan. Following which few more cases of pneumonia with such unknown etiology were identified in Wuhan by the end of 2019. The chronology of the COVID-19 pandemic is explained in Figure 1. [15-18]

According to the WHO Weekly Epidemiological update, there are globally 110,763,898 confirmed cases and 2,455,331 deaths, distributed across six WHO regions [Table 1]. The highest number of confirmed cases and deaths are reported from the Region of Americas, whereas the least number of cases and deaths have been reported from the Western Pacific region.[19]

As of February 21, 2021, more than 70% of the burden is contributed by only 13 countries namely the USA, India, Brazil, Russia, the United Kingdom, France, Spain, Italy, Turkey, Germany, Colombia, Argentina, Mexico, the USA, and India altogether contribute approximately 35% of the total global burden. A similar trend is observed in terms of mortality associated with COVID-19 cases, with 12 countries contributing to more than 70% of the deaths related to the disease globally.[20]

SARS-CoV-2 is an RNA coronavirus that is susceptible to faster mutations, eventually the emergence of various mutated strains across the globe. In the past couple of months, multiple variants of the virus are reported globally such as UK variant: B.1.1.7, South African variant: B.1.351, and Brazilian variant: P 1.[21] The UK variant was estimated to be 71% more infectious than previous strain.[22] New variants namely N440K and E484Q have been detected in Maharashtra and Kerala, but there is no direct evidence that suggests the two strains have caused a resurgence of COVID-19 cases in these states.[23]

**Table 1: Distribution of COVID-19 cases and deaths across six WHO regions**

| WHO Region       | Cumulative cases (%) | Cumulative deaths (%) | Case fatality rate in % |
|------------------|----------------------|-----------------------|-------------------------|
| Americas         | 49,296,115 (45%)     | 1,171,294 (48%)       | 2.4                     |
| Europe           | 37,574,211 (34%)     | 838,761 (34%)         | 2.2                     |
| South-East Asia  | 13,345,990 (12%)     | 204,796 (8%)          | 1.5                     |
| Eastern Mediterranean | 16,181,023 (6%)   | 141,915 (6%)          | 2.3                     |
| Africa           | 2,789,884 (3%)       | 70,332 (3%)           | 2.2                     |
| Western Pacific  | 1,576,330 (1%)       | 28,220 (1%)           | 1.8                     |
| Other            | 745 (<1)             | 13 (<1)               | 1.7                     |
| Global           | 110,763,898           | 2,455,331             | 2.2                     |

**Epidemic Curve of Infection**

The outbreak of the COVID-19 can be well understood by means of the epidemic curve of infection. Different countries of the world exhibit different curve patterns based on their demographics, the readiness of the health system to an epidemic, implementation of preventive measures (lockdown, social distancing), country’s reaction time to the pandemic, etc. Different phases may last for a different time period depending upon the above factor. However, the existing data suggest, increasing phase generally lasts for a minimum of 4 to 12 weeks or even more for COVID-19, based upon the measures taken in the particular country. The increasing phase is followed by the plateau phase which describes the stability of incidence cases. The plateau phase was initially achieved by several countries such as China, South Korea, Italy, Germany, France, Spain, Turkey, Belgium, Austria, Australia, Japan, New Zealand, and Malaysia by the month of May.[24] Initially, by June 10, nine countries: New Zealand, Tanzania, Vatican, Fiji, Montenegro, Seychelles, St Kitts and Nevis, Timor Leste, and Papua New Guinea have been declared free from COVID-19 in absence of active cases and following the recovery of their last case. Various countries entered the decreasing phase primarily; however, unlocking, relaxation of preventive measures, and changing human behaviors lead to a drastic increase in the number of COVID-19 cases resulting in a second wave of transmission. This resulted in reimposing lockdown measures in countries such as Nepal, Italy, France, Netherland, and Germany.[25] Furthermore, the discovery of new strains has also significantly contributed to increasing the number of cases.

**Incubation Period**

The incubation period of COVID-19 was defined as 6.4 days (95% CI: 5.6–7.7) ranging from 2.1 to 11.1 days.[26] The incubation
period averages around 5–6 days, but it ranges between 2 and 14 days.\textsuperscript{27,28} The mean incubation period in India is 5 days (ranges from 1 to 14 days).\textsuperscript{29}

Few studies have shown longer incubation periods of 19 and 24 days, extended up to 27 days.\textsuperscript{30-32} However, the WHO stated that a very long incubation period can be viewed as second exposure. Studies indicate that the incubation period varies greatly from person to person.\textsuperscript{33} As compared with other members of the family, the incubation period of COVID-19 was similar to MERS but slightly longer than SARS.\textsuperscript{34}

**Route of Transmission**

The major transmission routes of COVID-19 are through contact transmission and respiratory droplets generated during coughing and sneezing. These respiratory droplets infected with the virus can spread from 1 to 2 meters and can even deposit on surfaces as fomites. Infection is acquired either by inhalation of these virus-infected–droplets or by touching contaminated surfaces and then touching the nose, mouth, and eyes.\textsuperscript{35}

Moreover, the viability and stability of the virus also serve as the medium of transmission. The stability of the COVID-19 virus varies from 2 hours to 9 days at 30°C depending upon the surface of contact. The virus can be spotted in aerosols up to 3 h postaerosolization, up to 4 h on copper, up to 24 h on cardboard. The virus exhibits relatively longer viability on surfaces such as plastic and stainless steel as it can survive up to 2-to-3 days.\textsuperscript{36,37}

Nevertheless, evidence related to another possible transmission such as airborne transmission\textsuperscript{36} and oral-fecal transmission were suspected initially.\textsuperscript{38,39} However, later limited airborne transmission is possible as SARS-CoV-2 is viable for up to 3 h.\textsuperscript{34} Studies indicated the nonexistence of transmission of COVID-19 via vertical transmission during pregnancy as well as during breastfeeding.\textsuperscript{40,41}
Transmissibility and $R_0$

The basic reproduction number ($R_0$) of the COVID-19 virus is an indication of the transmissibility of the virus, representing the average number of new infections generated by an infectious person in an unexposed population. The initial reports from China revealed mean $R_0$ for COVID-19 ranged from 1.4 to 6.49. A study with 14 such studies demonstrated mean $R_0$ for COVID-19 was 3.28. However, the WHO estimated a considerably lower $R_0$ as 1.95. Data on real-time monitoring of the transmissibility in Europe suggested real-time $R_0$ for Italy is 3.1, Germany is 4.43, France is 6.56, and Spain is 3.95. However, different $R_0$ have been reported in the same geographical region by using different methods and assumptions.

Spectrum of Infection and Clinical Features

COVID-19 is considered a self-limiting infection. Most of the cases with mild symptoms recover within 14 days. The outcomes of the SARS-CoV-2 can be divided into five categories based on the severity of the disease: i) asymptotically infected persons, ii) mild to medium cases, iii) severe cases, iv) critical case, and v) death.

It is important to note asymptomatic infection or absence of clinical sign of symptoms with positive SARS-CoV-2 results is not latent but a potential source of human-to-human transmission and also contribute informing family clusters. Around 1.2% of the total infected cases were reported to be asymptomatic in Chinese studies. However, studies from Diamond Princess and Japan reported an asymptomatic infection rate as high as 18%.

Mild and moderate symptoms such as fever, fatigue, myalgia, dry cough, sore throat, runny nose, sneezing, and signs of mild pneumonia are likely to be present in 80.9% of the total coronavirus infected cases and generally do not require hospitalization. Respiratory symptoms such as cough and dyspnea (or tachypnea in children) are likely to be present without signs of severe pneumonia in moderate cases.

Severe cases can be characterized by the presence of severe pneumonia, severe acute respiratory distress syndrome, sepsis, and septic shock. It is present in 13.8% of the cases. Critical cases are found to be 4.7% which suffer respiratory failure, septic shock including multiple organ dysfunction. These cases require critical care and ventilators for management. Death is present in 2.3% of the cases.

A recent meta-analysis stated fever (77.6%) and cough (64.8%) as the most common symptoms. In addition to this symptoms such as headache (15.2%), diarrhea (11.8%), olfactory disorders (10.1%), and gustatory disorders (10.0%) were also reported.

Susceptible Population

People of every age group and both genders are susceptible to this transmissible virus. Initially, women were considered to be less susceptible as compared to men, primarily because of different innate immunity, steroid hormones, and factors related to sex chromosomes; however, at present no such difference is observed.

The virus infects people from all age groups, but more cases were reported from the middle-aged group mainly, probably due to their higher mobility and social connection. The studies have indicated the severity of the disease depends upon the age of the infected person. The proportion of SARS-CoV-2 patients to be hospitalized increases with age up to a maximum of 18-4%, especially in patients above 80 years. The comparative analysis among ICU cases with non-ICU cases from Wuhan suggested the median age of hospitalization was significantly higher in the ICU group (66 years, IQR: 57–78 years vs 51 years, IQR: 37–62 years). In addition to age, the presence of comorbidities also determines the course of infection. The Wuhan study stated ICU patients were more likely to have comorbidities such as diabetes (22.2% vs 5.9%), hypertension (58.3% vs 21.6%), and cardiovascular disease (CVD) (25.0% vs 10.8%) when compared to non-ICU patients.

Case Fatality Rate

The overall case fatality rate is 2.2% according to the WHO Weekly Epidemiological Update as of February 21, 2021. Nevertheless, the mortality rate varies across WHO regions as well as between countries. The exceptionally high mortality was reported from the WHO-European region (4.4%) in the initial few months, majorly contributed by Spain, Italy, France, and the United Kingdom.

Moreover, it was hypothesized that the countries with older population have higher case fatality rates and similarly, the pre-existing comorbid condition can increase fatality rate by 10.5% for CVD, 6.3% for chronic respiratory disease, 6.0% for hypertension, 7.3% for diabetes, and 5.6% for cancer. The initial assessments suggest that mutant strains having similar clinical presentation or severity and are not associated with increased deaths.

Diagnosis

Diagnosis of infection with self-limited nature and mild-moderate symptoms is avoidable, but in the case of the novel coronavirus, it is crucial to identify the etiological agent which is highly contagious. Earlier, the diagnosis of the novel coronavirus was based on the combination of epidemiological risks, clinical features, and laboratory tests. People who had a history of travel from China or close contact with a confirmed or suspected case of COVID-19, and present with clinical symptoms within the incubation period were suspected and administered laboratory testing.

Diagnostic strategies such as nucleic acid amplification of viral antigen through reverse-transcription polymerase
chain reaction (RT-PCR), real-time RT-PCR (rRT-PCR), and reverse transcription loop-mediated isothermal amplification (RT-LAMP), and microarray-based assays were used as confirmatory tests. The nucleic acid can be detected in nasopharyngeal swabs, sputum, lower respiratory tract secretions, blood, and stool. Later, increasing cases with local transmission, the WHO guidelines were revised several times.

In addition to the nucleic acid test, other diagnostic tools include CRISPR. It is a genome editing technology developed by the Institute of Genomics and Integrative Biology (IGIB) which has similar accuracy as traditional RT-PCR tests but has a quicker turnaround time and requires less expensive equipment and, hence, better ease of use. At present, many commercial tools such as paper strips which work on antigen-antibody principles have been approved by various organizations. These paper strips work well when the virus is actively replicating i.e. during acute infection.

Recently, a newer test Paper-based RAY (Rapid variant Assay), which is much quicker than genome sequencing has been identified. It can also identify three variants with the common mutation N501Y from the UK, South Africa, and Brazil.

**Treatment**

At present, there is no specific treatment available for patients with COVID-19 infection rather it is essentially supportive and symptomatic. However, already existing antivirals lopinavir, ribavirin, and remdesivir and antimalarial drugs-Chloroquine and Hydroxychloroquine approved for other recommendations were considered potential candidates in the treatment of COVID-19. However, the interim results of the Solidarity Trial found all four treatments (remdesivir, hydroxychloroquine, lopinavir/ritonavir, and interferon) had little or no effect on overall mortality, instigation of ventilation, and duration of hospital stay in hospitalized patients. Over time, the treatment shifted towards use of dexamethasone and ivermectin. Nowadays, a mixed approach is being used to treat the patients of COVID-19. Convalescent plasma transfusion is another technique that has shown significant improvement in the survival of critical patients. Though plasma therapy has shown positive results, its complexity of extracting the plasma restricts its wider clinical application.

**Prevention**

As there are no approved treatments for this infection, hence, prevention is a crucial and necessary step. However, asymptomatic nature, non-specific and overlapping feature of the disease, its contagious nature during the incubation period, and prolonged duration of the illness are some peculiar characteristics of the virus that makes prevention difficult. These properties re-emphasize the importance of prevention.

At the personal level, isolation of confirmed or suspected cases from apparently healthy individuals. Use of any type of mask, following respiratory etiquettes, and hand hygiene are highly recommended for all, irrespective of the case or noncase of COVID-19. Cleaning the frequently used surfaces with surface disinfections such as 62%–71% ethanol, 0.5% hydrogen peroxide, or 0.1% sodium hypochlorite can efficiently inactivate the virus. Apart from this, social distancing should be maintained. At the community level, avoidance of crowded areas and postponement of nonessential travel to places should be avoided.

Several countries have taken legislative steps to curb the disease by restricting the flights from affected areas, screening people at airport and seaports, closing down nonessential services, and announcing a complete lockdown in the country. A nationwide 21-days lockdown was implemented in India on March 23, 2020 and with the incessantly increase in cases, an extended phase two of lockdown was imposed till May 3, 2020, which subsequently prolonged till May 17, 2020 and later continued till May 31, 2020. To make the lockdown and social distancing effective, India also levied the quarantine law under the Epidemic Disease Act, 1897. The unlocking was done in a phased manner with having continued lockdown in a modified manner in certain parts of the country such as weekend restrictions, movement limitation after a particular time, or closure of some services like continuing closing of educational institutes. However, a drastic decrease has been seen in the number of cases as of February 21, 2020, which has eventually resulted in the opening of the above-mentioned services. With a dearth of specific treatment, movement restriction and social distancing still hold immense importance in the containment of the spread of novel coronavirus.

In addition to the above-mentioned preventive measures, the development of a safe and effective vaccine against COVID-19 has been a breakthrough event in less than a year, a process known to take a decade or more. The normal time frame for vaccine development was greatly squeezed because of the raging pandemic, and there has been a total paradigm shift from the traditional approach in clinical trials, approvals for public deployment, and subsequent production.

To date more than 200 vaccine candidates are in the development phase, out of which more than 60 are in the clinical development phase, and 12 vaccines have been approved and rolled out in several countries. As per the update on February 26, 2021, more than 225 million doses of COVID-19 vaccine have been administered across 100 countries with a rate of approximately 6 million doses per day. There is limited data available with respect to the safety of the vaccine; however, no conclusive evidence on adverse effects following immunization has been generated to date. Furthermore, the status of effectiveness of these vaccines is unclear with respect to newer strains.

**Conclusion**

This novel virus pandemic has been a public health challenge to the entire world over 1 year of its origin. The trends
suggested the unlocking in absence of preventive measures can drastically increase the COVID-19 cases. Thus, there is a need to reemphasizing hand hygiene and respiratory etiquettes and continuing the practice of preventive measures even after the

| Name                                                      | Mechanism                          | Doses                              | Efficacy  | Storage                                               | Status                                                                                                                                 |
|-----------------------------------------------------------|------------------------------------|------------------------------------|-----------|-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Pfizer-BioNTech: Comirnaty (also known as tozinameran or BNT162b2) | mRNA                               | 2 doses, 3 weeks apart             | 95%       | Freezer storage only at −13°F to 5°F (−25°C to −15°C) | Approved in Bahrain, Brazil, New Zealand, Saudi Arabia, Switzerland. Emergency use in other countries (Argentina, Australia, Canada, Chile, Colombia, Costa Rica, Ecuador, European Union, Hong Kong, Iceland, Iraq, Israel, Japan, Jordan, Kuwait, Lebanon, Malaysia, Moldova NEW, Mongolia, Norway, Oman, Panama, Peru, Philippines, Qatar, Serbia, Singapore, Tunisia, United Arab Emirates, United Kingdom, United States) |
| Moderna: mRNA-1273                                        | mRNA                               | 2 doses, 4 weeks apart             | 94.5%     | 30 days with refrigeration, 6 months at −4°F (−20°C)  | Emergency use in Canada, European Union, Iceland, Israel, Mongolia, Norway, Qatar, Singapore, United Kingdom, United States.            |
| Gamaleya: Sputnik V (also known as Gam-COVID-Vac)          | A combination of two adenoviruses Ad5 and Ad26. | 2 doses, 3 weeks apart             | 92%       | Freezer storage. Developing an alternative formulation that can be refrigerated. | Early use in Russia. Emergency use in other countries (Algeria, Argentina, Armenia, Bahrain, Belarus, Bolivia, Bosnian Serb Republic, Egypt, Honduras, Gabon, Ghana, Guatemala, Guinea, Guyana, Hungary, Iran, Kazakhstan, Kyrgyzstan, Lebanon, Mexico, Moldova NEW, Mongolia, Montenegro, Myanmar, Nicaragua, Pakistan, Palestinian Authority, Paraguay, San Marino, St. Vincent and the Grenadines, Serbia, Syria NEW, Tunisia, Turkmenistan, United Arab Emirates, Uzbekistan, Venezuela.) |
| Oxford-AstraZeneca: AZD1222 (Covishield in India)         | ChAdOx1                             | 2 doses, 12 weeks apart            | 82.4%     | Stable in the refrigerator for at least 6 months     | Emergency use in U.K., E.U., other countries.                                                                                         |
| CanSino: Convidecia (also known as Ad5-nCoV)               | Adenovirus Ad5                      | 1 dose                             | 65.3%     | Refrigerated                                         | Approved in China. Emergency use in Pakistan, Mexico.                                                                               |
| Johnson & Johnson: Ad26.COV2.5                            | Ad26                               | 1 dose                             | 72%       | Up to two years frozen at −4°F (−20°C), and up to three months refrigerated at 36–46°F (2–8°C). | Emergency use in Bahrain, United States.                                                                                                                                                          |
| Vector Institute: EpiVacCorona                            | Protein                             | 2 doses, 3 weeks apart             | Unknown   | Stable in the refrigerator for up to two years       | Early use in Russia                                                                                                                                                                             |
| Novavax: NVX-CoV2373                                       | Protein                             | 2 doses, 3 weeks apart             | 89.3%     | Stable in refrigerator                               | Agreement with Serum Institute of India to 2 billion doses a year. Agreement to supply to other countries: United States, United Kingdom, Canada, Australia, and South Korea. |
| Sinopharm: BBIBP-CorV                                      | Inactivated form of the coronavirus | 2 doses, 3 weeks apart             | 72.5%     | -                                                    | Approved for use in Bahrain, China, United Arab Emirates. Emergency use in Argentina, Cambodia, Egypt, Guyana, Hungary, Iraq, Jordan, Nepal, Pakistan, Peru. Limited use in Serbia, Seychelles. |
| Sinovac: CoronaVac (formerly PiCoVacc)                     | Inactivated form of the coronavirus | 2 doses, 2 weeks apart             | 50.38%    | Refrigerated                                         | Approved for use in China. Emergency use in Azerbaijan, Brazil, Chile, Colombia, Ecuador NEW, Hong Kong, Indonesia, Laos, Mexico, Philippines, Thailand, Turkey, Uruguay. |
| Bharat Biotech: Covaxin (also known as BBV152 A, B, C)     | Inactivated form of the coronavirus | 2 doses, 4 weeks apart             | 78%       | At least a week at room temperature                 | Approved for use in India                                                                                                                                                                          |
| CoviVac                                                    | live attenuated vaccine             | 2 doses, 2 weeks apart             | Unknown   | 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit)     | Approved for use in Russia                                                                                                                                                                        |
advent of the vaccine is important in containing the new strains of the coronavirus. The coming days will suggest how the new strains of the virus will impact our lives; however, the primary care physicians need to be aware of the updated knowledge about the ever-changing pandemic for better prevention, diagnosis, and management of the disease.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Decaro N, Mari V, Desario C, Campolo M, Elia G, Martella V, *et al*. Severe outbreak of bovine coronavirus infection in dairy cattle during the warmer season. Vet Microbiol 2008;126:30-9.
2. Rubenstein D, Tyrrell DA, Derbyshire JB, Collins AP. Growth of porcine transmissible gastroenteritis (TGE) virus in organ cultures of pig tissue. Nature 1970;227:1348-9.
3. Cherry JD. The chronology of the 2002-2003 SARS mini pandemic. Paediatr Respir Rev 2004;5:262-9.
4. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, *et al*. Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the coronavirus study group. J Virol 2013;87:7790-2.
5. WHO. Pneumonia of unknown cause – China. WHO. World Health Organization. Available from: http://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/. [Last accessed on 2020 Apr 25].
6. Naming the coronavirus disease (COVID-19) and the virus that causes it. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-19)‑and‑the‑virus‑that-causes‑it. [Last accessed on 2020 Apr 25].
7. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Available from: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee‑regarding‑the‑outbreak‑of‑novel‑coronavirus‑(2019‑ncov). [Last accessed on 2020 Apr 25].
8. WHO Director-General’s opening remarks at the media briefing on COVID-19 11 March 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020. [Last accessed on 2020 Apr 25].
9. Weekly epidemiological update-23 February 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update—23-february-2021. [Last accessed on 2021 Feb 26].
10. World Health Organization. COVID-19 vaccines. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines. [Last accessed on 2021 Mar 1].
11. Tyrrell DAJ, Myint SH. Coronaviruses. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996.
12. Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, *et al*. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9:221-36.
13. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181-92.
14. Yu P, Hu B, Shi Z-L, Cui J. Geographical structure of bat SARS-related coronaviruses. Infect Genet Evol 2019;69:224-9.
15. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141-54.
16. GRID COVID-19 Study Group. Combating the COVID-19 pandemic in a resource-constrained setting: Insights from initial response in India. BMJ Glob Health 2020;5. doi: 10.1136/bmjgh-2020-003416.
17. Timeline: WHO’s COVID-19 response. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline. [Last accessed on 2021 Mar 2].
18. Indian Council of Medical Research. COVID-19 Time line. 2021. Available from: https://www.icmr.gov.in/COVIDTimeline/index.html. [Last accessed on 2021 Jun 4].
19. World Health Organisation. Weekly Epidemiological Update Coronavirus disease 2019 (COVID-19) 20 October 2020. 2020 Oct. (Weekly Epidemiological Update). Report No.: 10.
20. World Health Organisation. Weekly epidemiological update-23 February 2021. World Health Organisation; 2021. (COVID-19 Weekly Epidemiological Update). Report No.: 28. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update—23-february-2021. [Last accessed on 2021 Mar 1].
21. World Health Organisation. WHO | SARS-CoV-2 Variants. WHO. World Health Organization; 2020. Available from: http://www.who.int/publications/m/item/weekly-epidemiological-update—23-february-2021. [Last accessed on 2021 Mar 1].
22. Mahase E. Covid-19: What have we learnt about the new variant in the UK? BMJ 2020;371:m4944. Available from: https://www.bmj.com/content/371/bmj.m4944. [Last accessed on 2021 Mar 1].
23. Dey S. Surge in Maharashtra and Kerala not linked to new strains, says ICMR DG | India News-Times of India. The Times of India 2021. Available from: https://timesofindia.indiatimes.com/india/surge-in-maharashtra-kerala-not-linked-to-new-strains-says-icmr-dg/articleshow/81177312.cms. [Last accessed on 2021 Mar 1].
24. World Health Organisation. Novel Coronavirus (2019-nCoV) Situation Report-19. 2020 Feb. (Situation Report). Report No.: 19. Available from: https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-2019/interactive-timeline. [Last accessed on 2021 Mar 1].
25. Coronavirus Update (Live): 42,489,901 Cases and 1,149,229 Deaths from COVID-19 Virus Pandemic-Worldometer. Available from: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1%20%5Cl%20%22countries%3Ca%20href=. [Last accessed on 2020 Oct 24].
26. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill 2020;25:200062. doi: 10.2807/1560-7917.
27. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: A statistical analysis of publicly available case data. J Clin Med 2020;9:538. doi: 10.3390/jcm9050538.

28. World Health Organisation. Coronavirus disease 2019 (COVID-19) Situation Report-73. World Health Organization; 2020 Apr. (Situation Report. Report No.: 73. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_6.

29. National Health Mission. Detail Question and Answers on COVID-19 for Public. Government of Karnataka. Available from: https://www.mohfw.gov.in/pdf/FAQ.pdf.

30. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of 2019 novel coronavirus infections in China. medRxiv 2020;2020.02.06.20020974. Available from: https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1. [Last accessed on 2020 Apr 27].

31. Coronavirus incubation could be as long as 27 days, Chinese provincial government says. Reuters 2020. Available from: https://www.reuters.com/article/us-china-health-incubation-idUSKCN20G06W. [Last accessed on 2020 Apr 27].

32. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen I, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406-7.

33. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 2020;395:514-23.

34. Jiang X, Rayner S, Luo M. Does SARS-CoV-2 has a longer incubation period than SARS and MERS? J Med Virol 2020;92:476-9.

35. Modes of transmission of virus causing COVID-19: Implications for IPC precaution recommendations. [Last accessed on 2020 Apr 27].

36. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564-7.

37. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104:246-51.

38. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323:1843-4.

39. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581:465-9.

40. Dashraath P, Wong JJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020;222:521-31.

41. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: Maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med 2020;144:799-805.
Rastogi, et al.: Epidemiology of COVID-19

58. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.

59. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020;55:105955. doi: 10.1016/j.ijantimicag.2020.105955.

60. DCGL approves commercial launch of low cost Covid-19 test “Feluda” | Council of Scientific and Industrial Research | CSIR | GoI. Available from: https://www.csir.res.in/slider/dcgl-approves-commercial-launch-low-cost-covid-19-test-feluda. [Last accessed on 2021 Feb 27].

61. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. Available from: https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19. [Last accessed on 2020 Apr 27].

62. Basu M. After FELUDA, CSIR develops paper test “RAY” to identify Covid variants within an hour. ThePrint 2021. Available from: https://theprint.in/health/after-feluda-csir-develops-paper-test-ray-to-identify-covid-variants-within-an-hour/599054/. [Last accessed on 2021 Feb 27].

63. Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MML, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study. Hong Kong Med J 2003;9:399-406.

64. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477. Available from: http://www.sciencedirect.com/science/article/pii/S0024320520302253. [Last accessed on 2020 Apr 27].

65. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9. Available from: https://stm.sciencemag.org/content/9/396/eaal3653. [Last accessed on 2020 Apr 27].

66. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72-3.

67. World Health Organisation. “Solidarity” clinical trial for COVID-19 treatments. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control. [Last accessed on 2020 Apr 27].

68. World Health Organisation, India. Novel Coronavirus Disease (COVID-19) Situation Update Report-10. India; 2019. Available from: https://www.who.int/docs/default-source/india-situation-report/india-situation-report-10.pdf?sfvrsn=5ca2a672_0.

69. World Health Organisation, India. Novel Coronavirus Disease (COVID-19) Situation Update Report-16. India; 2020. Available from: https://www.who.int/docs/default-source/india-situation-report/india-situation-report-16.pdf?sfvrsn=7a583424_2.

70. COVID-19 vaccines. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines. [Last accessed on 2021 Feb 26].

71. More Than 225 Million Shots Given: Covid-19 Tracker. Bloomberg.com; Available from: https://www.bloomberg.com/graphics/covid-vaccine-tracker ‑global-distribution/. [Last accessed on 2021 Feb 26].

72. World Health Organization, COVID-19 Vaccines: Safety Surveillance Manual. 2020. Available from: https://www.who.int/docs/default-source/wrindia/india-situation-report-1. pdf?sfvrsn=5ca2a672_0.

73. World Health Organization, COVID-19 Vaccines: Safety Surveillance Manual. 2020. Available from: https://www.who.int/docs/default-source/wrindia/india-situation-report/india-situation-report-11.pdf?sfvrsn=7a583424_2.

74. World Health Organisation, India. Novel Coronavirus Disease (COVID-19) Situation Update Report-10. India; 2019. Available from: https://www.who.int/docs/default-source/india-situation-report/india-situation-report-10.pdf?sfvrsn=5ca2a672_0.

75. World Health Organisation, India. Novel Coronavirus Disease (COVID-19) Situation Update Report-16. India; 2020. Available from: https://www.who.int/docs/default-source/india-situation-report/india-situation-report-16.pdf?sfvrsn=7a583424_2.

76. World Health Organisation, India. Novel Coronavirus Disease (COVID-19) Situation Update Report-16. India; 2020. Available from: https://www.who.int/docs/default-source/india-situation-report/india-situation-report-16.pdf?sfvrsn=7a583424_2.

77. COVID-19 vaccines. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines. [Last accessed on 2021 Feb 26].

78. More Than 225 Million Shots Given: Covid-19 Tracker. Bloomberg.com; Available from: https://www.bloomberg.com/graphics/covid-vaccine-tracker ‑global-distribution/. [Last accessed on 2021 Feb 26].

79. World Health Organization, COVID-19 Vaccines: Safety Surveillance Manual. 2020. Available from: https://www.who.int/docs/default-source/wrindia/india-situation-report-1. pdf?sfvrsn=5ca2a672_0.

80. Zimmer C, Corum J, Wee S-L. Coronavirus vaccine tracker. The New York Times. Available from: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html. [Last accessed on 2021 Mar 3].

81. Polack FP, Thomas SJ, Kitchin N, Absalon J, Kurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15.

82. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397:671-81.

83. Logunov DY, Dolzhikova IV, Shchelbyakov DV, Tukhvatulin AI, Zubkova OV, Dzharuullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.

84. Voisyse M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.

85. PharmD KL, Carlson R, Reiter D. Convidicea Vaccine 2021.
86. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021;384:1824-35.

87. Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector." Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase). clinicaltrials.gov; 2021 Feb. Report No.: NCT04527575. Available from: https://clinicaltrials.gov/ct2/show/NCT04527575. [Last accessed on 2021 Mar 1].

88. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial | Novavax Inc.-IR Site. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-effficacy-uk-phase-3. [Last accessed on 2021 Mar 3].

89. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21:39-51.

90. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-92.

91. Ganneru B, Jogdand H, Dharam VK, Molugu NR, Prasad SD, Vellimudu S, et al. Evaluation of safety and immunogenicity of an adjuvanted, TH-1 skewed, whole virion inactivated SARS-CoV-2 vaccine-BBV152. bioRxiv 2020;2020.09.09.285445. Available from: https://www.biorxiv.org/content/10.1101/2020.09.09.285445v2. [Last accessed on 2021 Mar 3].

92. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021;21:637-46.

93. Codagenix, Inc. First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19. clinicaltrials.gov; 2020. Report No.: NCT04619628. Available from: https://clinicaltrials.gov/ct2/show/NCT04619628. [Last accessed on 2021 Mar 1].